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Background
Pivotal studies with anti-CTLA-4 (Ipilimumab or IPI)
demonstrated increased overall survival (OS) both as
single agent (10.1 months) and with DTIC (11.2 months).
We’ve previously reported an encouraging safety profile
with IPI plus CP and early efficacy results. We now report
updated 1-year OS and immune biomarker correlates of
patient response.
Methods
30 patients were randomized in a 1:2 ratio to arm A (C
(AUC=6) and P (175mg/m2) every 3 weeks × 5 and IPI
(3mg/kg) every 3 weeks × 4 starting at week 4) or arm B
(similar dosing to arm A except IPI was given on week
after CP). Tumor biopsies were collected at screening and
week 8, and immune monitoring bloods were collected
throughout.
Results
Median OS was 16.1 months, with a 1-year OS of 56.5%
for all patients with no differences between arms. Overall
median follow-up was 23.2 months. Best overall response
rate (BORR) and disease control rate (DCR) were 26.7%
and 56.7% by irRC. BORR in patients whose tumors were
wild type for BRAF and NRAS was 44%, compared to 8%
in patients with a mutation in BRAF or NRAS. Clinical
responses correlated with the abundance of peri and
intratumoral CD3+ inflammatory cells in the pretreatment
biopsy, but not with CD4/CD8 ratios or CD20 infiltrate.
Circulating levels of some chemokines were elevated in
non-responders compared to responders. While IPI influ-
enced B cells and monocyte differentiation, this did not
correlate with clinical outcome. Lower levels of PD-1 on
CD4 and CD8 T cells were observed in responders com-
pared to non-responders.
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